Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study-Reference-Cited by-同舟云学术

Clinical outcomes in chronic hepatitis C long-term responders to pre-direct antiviral agents: a single-center retrospective study

Published:2019-07 Issue:5 Volume:110 Page:
ISSN:0026-4806
Container-title:Minerva Medica
language:
Short-container-title:Minerva Med

Author:

Rosso Chiara,Caviglia Gian Paolo,Ciruolo Michela,Ciancio Alessia,Younes Ramy,Olivero Antonella,Giordanino Chiara,Troshina Giulia,Abate Maria Lorena,Rizzetto Mario,Pellicano Rinaldo,Saracco Giorgio M.,Bugianesi Elisabetta,Smedile Antonina

Publisher

Edizioni Minerva Medica

Subject

General Medicine

Link

https://www.minervamedica.it/pdf.php?cod=R10Y2019N05A0401

Reference39 articles.

1. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy

2. IL28Bpolymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients

3. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

4. Diagnosis, management, and treatment of hepatitis C

5. Practice guidelines for the treatment of hepatitis C: Recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nichtalkoholische Fettleber – Diagnose und Therapie in 2022;Schweizer Gastroenterologie;2023-03

2. Chronic Hepatitis C: Pathophysiology and Clinical Issues;Biology;2022-11-29

3. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection;World Journal of Hepatology;2022-06-27

4. Triglyceride-glucose index and hepatic steatosis index for the assessment of liver steatosis in HCV patients;Minerva Gastroenterology;2022-03

5. A pharmacogenetic study in HIV-infected patients treated with ritonavir: hematological and cardiovascular disease risk analysis;Minerva Biotechnology and Biomolecular Research;2022-01